Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

280Bio Showcases Preclinical Findings for Novel KRAS Inhibitor

publication date: Mar 21, 2023

280Bio, a precision oncology company, will present preclinical data on TEB-17231, its lead KRAS Inhibitor candidate, at April’s AACR annual meeting. In the tests, the molecule blocked tumor growth and overcame KRASG12C inhibitor mediated resistance. 280Bio’s portfolio consists of novel oral oncology drug candidates directed at frequently mutated genetic changes in signaling pathways and the genetic instability features of many cancers. Headquartered in the San Francisco Bay Area, 280Bio is a subsidiary of Shanghai Yingli Pharma. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here